Sugi Predict

Sugi Predict / Targets / PPP1R12A

PPP1R12A

Protein phosphatase 1 regulatory subunit 12A · O14974 · PPP1R12A on Sugi Atlas →

1,894 patent compounds predicted against PPP1R12A, 1,677 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to PPP1R12A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Studying Phosphorus Metabolism nanCOMPLETED
Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography nanACTIVE_NOT_RECRUITING
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer nanWITHDRAWN
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas nanNOT_YET_RECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP1R12A binder may also engage these)

ProteinNameSimilarity
Q10728 — 1.000 Q10728 →
Q6DRG7 — 1.000 Q6DRG7 →
Q9DBR7 — 1.000 Q9DBR7 →
Q90623 — 1.000 Q90623 →
O60237 — 0.995 O60237 →
Q8BG95 — 0.994 Q8BG95 →
P97868 — 0.990 P97868 →
Q9XTT4 — 0.988 Q9XTT4 →
Q05D44 — 0.988 Q05D44 →
Q8NDI1 — 0.988 Q8NDI1 →
F1QIC4 — 0.988 F1QIC4 →
O75167 — 0.988 O75167 →
Q9NQW6 — 0.988 Q9NQW6 →
Q7YSI9 — 0.988 Q7YSI9 →
P48193 — 0.987 P48193 →
Q23551 — 0.987 Q23551 →
P12297 — 0.987 P12297 →
Q95XU6 — 0.987 Q95XU6 →
Q80TN7 — 0.987 Q80TN7 →
Q5TZ18 — 0.987 Q5TZ18 →
Q96B97 — 0.987 Q96B97 →
A6QP06 — 0.987 A6QP06 →
EPB41 Protein 4.1 0.987 landscape →
EPB41L2 Band 4.1-like protein 2 0.987 landscape →
Q69ZW3 — 0.987 Q69ZW3 →
Q2KNA0 — 0.987 Q2KNA0 →
Q9D824 — 0.986 Q9D824 →
Q1MTR4 — 0.986 Q1MTR4 →
Q8K0V4 — 0.986 Q8K0V4 →
A0JMK9 — 0.986 A0JMK9 →